Request Demo
Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug
License out/inPhase 2Phase 1Clinical Result
iStock,
utah778
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble Guanylate Cyclase activatorGuanylate Cyclase activator.
Roivant Sciences on Tuesday
debuted its newest spinout venture
Pulmovant, which will focus on the development of the investigational soluble Guanylate Cyclase activator mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease.
In a deal also announced Tuesday, Roivant in-licensed worldwide rights to mosliciguat from Bayer for an upfront payment of $14 million and the promise of up to $280 million in future development, regulatory and commercial milestones. Bayer will also be eligible for tiered high-single digit royalties on mosliciguat’s sales.
Pulmovant will advance mosliciguat through Phase II development, with the mid-stage PHocus study set to “begin imminently,” according to an
investor presentation
. Initial data from PHocus could come as early as the second half of 2026. If mosliciguat’s Phase II findings are positive, Roivant estimates that a single registrational trial could be enough to pave the way for its approval.
“We believe mosliciguat can transform the lives of patients living with pulmonary hypertension,” Roivant CEO Matt Gline said in a statement, noting mosliciguat’s “differentiated mechanism of action” can lead to “maximal impact on PH-ILD (pulmonary hypertension associated with interstitial lung disease) patients.”
Designed to be an inhaled therapy, mosliciguat is an activator of the soluble guanylate cyclase (sGC) enzyme, which is central to a complicated signaling cascade that culminates in the widening of blood vessels. By activating sGC, mosliciguat offers a new and potentially best-in-category treatment option for PH-ILD, a disease that affects around 200,000 patients in the U.S. and Europe, with little or no effective treatments, according to Roivant.
Data from the Phase Ib ATMOS study, which Pulmovant presented at the 2024 Congress of the European Respiratory Society in Vienna, showed that at 1-mg, 2-mg and 4-mg doses, mosliciguat elicited a mean-max peak reduction of 25.9%, 38.1% and 36.3% in pulmonary vascular resistance from baseline, respectively. According to Roivant, this effect was “clinically meaningful” and is “one of the highest reductions seen” to date.
Early-stage data from 170 healthy volunteers also showed that mosliciguat is safe and well-tolerated, while its 40-hour half-life can also open more practical dosing schedules. “Mosliciguat has the incredibly rare advantage of potential differentiation across three separate key areas—efficacy, safety, and convenience in administration,” Gline said.
Tuesday’s announcement comes after Roivant in October 2023
scored a $7.1-billion windfall
from the sale of its inflammatory bowel disease candidate to Roche. RVT-3101, an investigational anti-TL1A antibody, was being developed by Televant Holdings, for ulcerative colitis and Crohn’s disease. The companies
closed the deal in December 2023
.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!